











IHBI'S VISION

The Institute of Health and Biomedical Innovation (IHBI) uses the latest technology and brings together the best minds from around the world to conduct research into ways of improving health and wellbeing



IHBI Research Themes

Health Determinants and Health Systems
Injury Prevention and Trauma Management
Chronic Disease and Ageing

Prevention Intervention Translation





IHBI members work in multiple locations

Kelvin Grove- QUT

>1,200 researchers

- Gardens Point- QUT
- Translational Research Institute & PAH
- Medical Engineering Research Facility (MERF)
- QLD Centre for Children's Health Research (CCHR)
- QIMR Berghofer



Research Centres at IHBI

- NHMRC Centre of Research Excellence in End of Life Care
- NHMRC Centre of Research Excellence in Reducing Healthcare Associated Infection
- Australian Centre for Health Services Innovation
- Australia-China Centre for Tissue Engineering & Regenerative Medicine
- Australian Prostate Cancer Research Centre
- Centre for Accident Research and Road Safety, Queensland
- Centre for Palliative Care Research and Education
- Contact Lens and Visual Optics Laboratory
- Dementia Collaborative Research Centre
- International Laboratory for Air Quality and Health
- Cancer and Ageing Research Centre
- ARC Industrial training Centre in Additive Biomanufacturing



Genomics Research Centre

Objectives

- Identify genes involved in common diseases
- Characterise gene structure and function
- Elucidate gene-gene, gene-environment interactions
- Develop diagnostic techniques and therapeutics
- Various disorders including:

Migraine, MS, CVD, Glaucoma, Memory, Concussion and Ageing

Genomics repository (~10,000) samples

- DNA from case-controls, pedigrees and cohorts e.g. Nambour, BC Biobank, tissue for MS
- Migraine: >100 families, 1200 matched case- controls, >3000 cases
- Norfolk Island genetic isolate



GRC Commercial activities and Capabilities

- Genomics genotyping, sequencing, expression, epigenetics
 - whole genome or individual gene, mitochondrial
 - extractions, DNA, RNA, miRNA, biobanking
 - MassARRAY, Illumina, ABI, Ion Torrent Suite, Rotorgene, Pyroseq
- Biostatistics and bioinformatics
 - database development, analysis, software, sequencing pipeline
- Molecular Diagnostics
 - neurogenetic disorders FHM1-3, EA2, SCA6, CADASIL and Epilepsy
 - HGSA listed, NATA accredited
 - Sanger, NGS (WES and targeted panels)
- Genomics Clinical Trial Centre
 - Phase I- III
 - MS, migraine, nutraceuticals, Alzheimers Disease
- Significant R & D contracts



Antroquinonol and AD

Antroquinonol

- Extracted from Antrodia Camphorata mushroom native to Taiwan
- numerous biological and pharmacological activities
- Ongoing cancer clinical trials
- Crosses blood-brain barrier
- Previous preliminary study showed Antroquinonol improved learning and memory deficits and reduced hippocampal Aβ levels in a transgenic mouse (Chang et. al., 2015)



Antroquinonol testing in an animal model for Alzheimers Disease study

Two studies:

- Preventative animal study funded by Advance Queensland Johnson & Johnson Innovation QuickFire Challenge
- 2. Therapeutic animal study funded by Golden Biotechnology





Testing in an animal model

- AD transgenic mouse model and related controls
- Treatment: Drug administrated daily for 2 months by oral gavage:
 - at 8 weeks of age for preventative study
 - at 8 months of age for therapeutic study
- Behavioural testing:
 - Open field
 - Flevated Plus maze and Y mazes
 - Object recognition test
 - Watermaze test
- Biochemical assays for AD and inflammatory markers for both studies
 Y Maze Activity: Test for Spontaneous Alternation














Object Recognition

Watermaze: training and testing







Next Steps

If the results are interesting...

- Clinical trials
 - Antroquinonol is already in human trials for cancer

Genomics Clinical Trial Centre

- Gold Coast
- Multidisciplinary team (Neurologists, neuropsychologists, clinicians, study coordinators)
- Alzheimer's Diseases Trials To date:
 - 5 Sponsored Clinical Trials (2 preventative and 3 therapeutic)
 - Randomized over 90 participants
 - >800 participants consented for eligibility screening
 - >2000 potential participants engaged in pre-screening discussions





Acknowledgements

Golden Biotechnology Corporation

Advance Queensland Johnson & Johnson Innovation QuickFire Challenge

